Chitosan/Kollicoat SR 30D film-coated pellets of aminosalicylates for colonic drug delivery

Journal of Pharmaceutical Sciences

Volumn 99, Issue 1, 2010, Pages 186-195

  Wei, He ^a,b   Fan, Li Fang ^a,c   Min, Bai ^b   Chang, Yong Zhen ^d   Bai, Xiang ^a   Qing, Du ^a   Feng, Wang ^e   Min, Qin ^f   De Ying, Cao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CSPC Pharmaceutical Technology Co Ltd   (China)

^c Hebei Yiling Pharmaceutical Group   (China)

^d Xingtai Medical College   (China)

^e National Institute for Communicable Disease Control and Prevention   (China)

^f Department of Otolaryngology and Head and Neck Surgery   (China)

Author keywords

5 ASA; Chitosan; Colonic drug delivery; Film coating; Inflammatory bowel disease; Pellets; Pharmacokinetics

Indexed keywords

CHITOSAN; MESALAZINE; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; FILM COATING; GASTROINTESTINAL TRACT; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; ORGAN WEIGHT; PLASMA CONCENTRATION-TIME CURVE; RAT; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 73949112826     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21810     Document Type: Article

References (35)

1. Meissner Y, Lamprecht A. 2008. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J Pharm Sci 97:2878-2891.
2. Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaili L, Refouvelet B, Pellequer Y, Lamprecht A. 2007. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release 123:211-218.
3. Klotz U. 2005. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis 37:381-388.
4. Schroder H, Campbell DE. 1972. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 13:539-551.
5. Crotty B, Jewell DP. 1992. Drug therapy of ulcerative colitis. Br J Clin Pharmacol 34:189-198.
6. Novis BH, Korzets Z, Chen P, Bernheim J. 1988. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 296:1442.
7. Loftus EV, Kane SV, Bjorkman D. 2004. Systematic review: Short-term adverse effects of 5-ASA agents in treatment of ulcerative colitis. Aliment Pharmacol Ther 19:179-189.
8. Friend DR. 2005. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 57:247-265.
9. Sinha VR, Kumria R. 2003. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 18:3-18.
10. McConnell EL, Murdan S, Basit AW. 2008. An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria. J Pharm Sci 97:3820-3829.
11. Jain A, Gupta Y, Jain SK. 2007. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci 10:86-128.
12. Sinha VR, Kumria R. 2001. Polysaccharides in colon-specific drug delivery. Int J Pharm 224:19-38.
13. Yang L. 2008. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. J Control Release 125:77-86.
14. Chourasia MK, Jain SK. 2004. Polysaccharides for colon targeted drug delivery. Drug Deliv 11:129-148.
15. Furda I. 1983. Unconventional sources of dietary fiber, physiological and in vitro functional properties. In: Furda I, editor. Aminopolysaccharides-Their potential as dietary fiber. Washington, DC: American Chemical Society. pp. 105-122.
16. Omrod DJ, Holmes CC, Miller TE. 1998. Dietary chitosan inhibits hypercholesterolaemia and atherogenesis in the apolipoprotein E-deficient mouse model of atherosclerosis. Atherosclerosis 138:329-334.
17. Vandamme TF, Lenourry A, Charrueau C, Chaumeil JC. 2002. The use of polysaccharides to target drugs to the colon. Carbohydr Polym 48:219-231.
18. He W, Fan LF, Du Q, Xiang B, Chang YZ, Cao DY. 2009. An investigation into the characteristics of chitosan/Kollicoat SR30D free films for colonic delivery. Eur J Pharm Biopharm 72:266-274.
19. He W, Du Q, Cao DY, Xiang B, Fan LF. 2008. In-vitro and in-vivo studies of pectin/ethylcellulose film-coated pellets of 5-fluorouracil for colonic targeting. J Pharm Pharmacol 60:35-44.
20. Nunthanid J, Huanbutta K, Luangtana-Anan M, Sriamornsak P, Limmatvapirat S, Puttipipatkhachorn S. 2008. Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose. Eur J Pharm Biopharm 68:253-259.
21. Katsuma M, Watanabe S, Kawai H, Takemura S, Masuda Y, Fukui M. 2002. Studies on lactulose formulations for colon-specific drug delivery. Int J Pharm 249:33-43.
22. Fedorak RN, Haeberlin B, Empey LR, Cui N, Nolen H III, Jewell LD. 1995. Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. Gastroenterology 108:1688-1699.
23. Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A. 2002. Chitosan capsules for colon-specific drug delivery: Enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release 82:51-61.
24. Yano H, Hirayama F, Arima H, Uekama K. 2001. Prednisolone-appended alpha-cyclodextrin: Alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6-trinitrobenzenesulfonic acid-induced colitis rats. J Pharm Sci 90:2103-2112.
25. Moore WEC, Holdeman LV. 1974. Human fecal flora: The normal flora of twenty Japanese-Hawaiians. Appl Microbiol 27:961-979.
26. Krawisz JE, Sharon P, Stenson WF. 1984. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344-1350.
27. Yue G, Sun FF, Dunn C, Yin K, Wong PY. 1996. The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. J Pharmacol Exp Ther 276:265-270.
28. He W, Du Q, Cao DY, Xiang B, Fan LF. 2008. Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. Int J Pharm 348:35-45.
29. Salyers AA, Leedle JA. 1983. Human intestinal microflora in health and disease. In: Hentge DJ, editor. Carbohydrate metabolism in the human colon. New York: Academic Press. pp. 129-146.
30. Finegold SM, Sutter VL, Sugihara PT, Elder HA, Lehmann SM, Phillips RL. 1977. Fecal microbial flora in Seventh Day Adventist populations and control subjects. Am J Clin Nutr 30:1781-1792.
31. Nielsen OH, Bondesen S. 1983. Kinetic of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 16:738-740.
32. Lichtenstein GR, Kamm MA. 2008. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis - Methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther 28:663-673.
33. Moore WEC, Holdeman LV. 1975. Discussion of current bacteriological investigations of the relationship between intestinal flora, diet and colon cancer. Cancer Res 35:3418-3420.
34. Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM. 1999. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 27:479-485.
35. Frieri G, Pimpo MT, Andreoli A, Annese V, Comberlato M, Corrao G, Palumbo G, Sturniolo GC, Tonelli F, Caprilli R. 1999. Prevention of postoperative recurrence of Crohn's disease requires adequate mucosal concentrations of mesalazine. Aliment Pharmacol Ther 13:557-582.